Kelun Pharmaceutical secures approval for RMB 4 bn super short-term financing

Sichuan Kelun Pharmaceutical Co., Ltd. announced on November 13, 2025, that its registration for super short-term commercial papers has been approved. The company received a "Notice of Acceptance of Registration" from the National Association of Financial Market Institutional Investors (NAFMII) on November 11, 2025. This approval allows the company to issue super short-term commercial papers with a registered amount of RMB 4 billion and a validity period of two years. CITIC Bank Co., Ltd. is designated as the lead underwriter for this issuance.

The resolution to issue non-financial enterprise debt financing instruments was initially approved by the company's Eighth Board of Directors on April 22, 2025, and subsequently by the 2024 Annual General Meeting on May 19, 2025. Related board and shareholder meeting resolutions were published on April 24, 2025, and May 20, 2025, respectively.

Sichuan Kelun Pharmaceutical plans to issue these papers in tranches, based on its funding needs and market conditions, and will promptly fulfill its information disclosure obligations. This move is expected to support the company's operational and strategic financing requirements.